Investor Presentation March 2022
Quarter Ended Mar 31, 2022
Q1 total revenue of $263.3 million, up 50% from $176.1 million for the prior-year quarter
Q1 net income of $12.1 million, compared to $14.5 million for the prior-year quarter
Q1 net income attributable to ApolloMed of $14.3 million, up 8% from $13.2 million for the prior-year quarter
For complete information regarding our financials, see our periodic filings
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner.